Statin vs Bempedoic Acid: Which Cholesterol Drug Is Right for You?

How Each Drug Works at the Molecular Level

Statins and bempedoic acid both reduce LDL cholesterol by targeting cholesterol biosynthesis, but they act at different steps in the same pathway. Statins block HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. Bempedoic acid sits one step earlier in the pathway, blocking ATP-citrate lyase (ACL), which converts citrate to acetyl-CoA before HMG-CoA is even formed.

That positional difference matters clinically. Bempedoic acid is a prodrug that requires activation by the enzyme ACSVL1 (very-long-chain acyl-CoA synthetase 1). ACSVL1 is present in hepatocytes but not in skeletal muscle. Because the drug stays inactive in muscle tissue, it does not cause the mitochondrial disruption and CoQ10 depletion that are thought to drive statin-associated muscle symptoms. Clinical pharmacology data for bempedoic acid are summarized in the FDA label.

Both drugs ultimately reduce hepatocyte cholesterol levels. The liver responds by upregulating LDL receptor expression, pulling more LDL particles out of circulation. The final LDL-lowering effect is larger with statins because HMG-CoA reductase is the rate-limiting step in the pathway; blocking the upstream ACL step yields a smaller net reduction in hepatic cholesterol synthesis.

One mechanistic detail that often gets missed: because both pathways converge on LDL receptor upregulation, the two drugs are partially additive rather than fully synergistic. Adding bempedoic acid to a maximally tolerated statin dose still produces a meaningful additional LDL-C drop of approximately 18% in patients already on background lipid therapy. This additive effect was confirmed in the CLEAR Harmony trial (N=2,230).

LDL-C and ApoB Reduction: What the Numbers Actually Show

LDL-C reduction is not the only number that matters. Particle count, measured as ApoB, predicts cardiovascular events better than LDL-C mass in several large analyses because each atherogenic lipoprotein carries exactly one ApoB molecule. A patient with elevated small-dense LDL may have a "normal" LDL-C but a dangerously high particle count.

High-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) reduce LDL-C by 50 to 55% and ApoB by approximately 38 to 45% in clinical trials. The 2018 AHA/ACC Cholesterol Guideline defines high-intensity statin therapy as producing LDL-C reductions of at least 50%. Moderate-intensity statins (e.g., atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg) reduce LDL-C by 30 to 49%.

Bempedoic acid 180 mg daily as monotherapy reduces LDL-C by 21 to 25% and ApoB by approximately 15 to 19% compared with placebo. In a pooled Phase 3 analysis (N=3,623), bempedoic acid monotherapy reduced LDL-C by 21.4% vs placebo (P<0.001). When added on top of a maximally tolerated statin, the incremental LDL-C reduction is 18% and incremental ApoB reduction is roughly 13%.

The fixed-dose combination tablet Nexlizet (bempedoic acid 180 mg plus ezetimibe 10 mg) produces LDL-C reductions of 36 to 38% from baseline, which approaches moderate-intensity statin territory. For a patient who genuinely cannot tolerate any statin, this combination offers a pathway to meaningful LDL and ApoB reduction without touching the mevalonate pathway at the HMG-CoA step.

One practical note on ApoB testing: the 2018 ACC/AHA guideline and the 2023 European Atherosclerosis Society both recommend measuring ApoB in patients whose LDL-C may underestimate risk, particularly those with metabolic syndrome, type 2 diabetes, or hypertriglyceridemia. The European Atherosclerosis Society 2023 Consensus Statement recommends ApoB as a primary treatment target for very-high-risk patients.

Cardiovascular Outcomes Evidence

Statins have the deepest cardiovascular outcomes data of any lipid-lowering drug class. The CTT Collaboration meta-analysis of 26 randomized trials (N=170,000) showed that each 1 mmol/L (roughly 39 mg/dL) reduction in LDL-C reduces major vascular events by 22%. Atorvastatin 80 mg reduced recurrent cardiovascular events by 16% vs atorvastatin 10 mg in the TNT trial (N=10,001). Rosuvastatin 20 mg reduced first cardiovascular events by 44% vs placebo in JUPITER (N=17,802). The CTT meta-analysis is available on The Lancet.

Bempedoic acid now has its own outcomes trial. CLEAR Outcomes (N=13,970; median follow-up 40.6 months) enrolled statin-intolerant patients with established cardiovascular disease or high risk. Bempedoic acid 180 mg reduced a four-component MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, or coronary revascularization) by 13% vs placebo (HR 0.87; 95% CI 0.79, 0.96; P=0.004). The CLEAR Outcomes trial was published in the New England Journal of Medicine in March 2023.

That 13% MACE reduction is meaningful. It is smaller than what high-intensity statins produce, but CLEAR Outcomes was explicitly designed for statin-intolerant patients. The study does not tell us whether bempedoic acid is inferior to statins head-to-head; it tells us bempedoic acid works in patients who have no good statin option.

For patients already on a maximally tolerated statin who still do not reach their LDL-C goal, the evidence hierarchy favors adding ezetimibe first (IMPROVE-IT trial, N=18,144 to 6.4% relative MACE reduction), then a PCSK9 inhibitor (FOURIER with evolocumab, N=27,564 to 15% relative MACE reduction), and then bempedoic acid as an additional oral option. IMPROVE-IT results are available on the New England Journal of Medicine site.

Side-Effect Profiles Side by Side

Statins. Myalgia is the most common complaint, reported by roughly 5 to 10% of patients in routine practice, though blinded trial rates are closer to 1 to 5%. Serious myopathy (CK >10 times the upper limit of normal) occurs in fewer than 1 in 10,000 patients per year. Rhabdomyolysis is rare but potentially fatal. Statins raise fasting glucose by approximately 0.1 mmol/L and increase new-onset diabetes risk by 9 to 12% in patients already at metabolic risk. A 2010 Lancet meta-analysis (N=91,140) confirmed the statin-diabetes association across five trials. Transaminase elevations above three times the upper limit of normal occur in fewer than 1% of patients.

Bempedoic acid. Muscle symptoms were no higher than placebo in Phase 3 trials, consistent with the drug's inability to activate in skeletal muscle. The main safety signals are:

• Hyperuricemia and gout. Bempedoic acid inhibits renal tubular uric acid secretion via OAT4. In CLEAR Outcomes, gout events occurred in 3.0% of patients on bempedoic acid vs 2.1% on placebo. Patients with a prior history of gout should be monitored carefully.
• Tendon rupture or injury. The Phase 3 program reported a small excess of tendon-related adverse events (0.5% vs 0.3% placebo), an effect that has been noted in the FDA label.
• Mild elevations in serum creatinine (non-progressive, not associated with true GFR decline based on cystatin C measurements in the trials).

The bempedoic acid FDA prescribing information summarizes all boxed warnings and adverse events.

Drug Interactions and Special Populations

Statins and simvastatin/lovastatin. These two statins are metabolized primarily by CYP3A4, so concomitant use of azole antifungals, clarithromycin, cyclosporine, or large quantities of grapefruit juice can increase plasma concentrations dramatically. Atorvastatin is also CYP3A4-dependent but has a wider therapeutic index. Rosuvastatin, pravastatin, and fluvastatin are not CYP3A4 substrates, making them preferable in patients on complex medication regimens.

Bempedoic acid and simvastatin/pravastatin. Bempedoic acid is an inhibitor of OATP1B1 and OATP1B3 transporters. Co-administration increases simvastatin exposure by approximately 2-fold and pravastatin exposure by roughly 2.3-fold. The FDA label limits simvastatin to 20 mg/day and pravastatin to 40 mg/day when used with bempedoic acid. This interaction is documented in the FDA prescribing information.

Pregnancy. Both drug classes are contraindicated in pregnancy. Statins inhibit cholesterol synthesis required for fetal development. Bempedoic acid has no adequate human data; animal studies showed embryofetal toxicity at exposures below the clinical dose.

Chronic kidney disease. Pravastatin and fluvastatin require no dose adjustment in CKD. Rosuvastatin should be capped at 10 mg/day in patients with eGFR <30 mL/min/1.73m². Bempedoic acid does not require dose adjustment in mild-to-moderate CKD, but limited data exist for eGFR <30.

Elderly patients. Statin myopathy risk increases with age, female sex, low body mass, and renal impairment. For older adults at high myopathy risk, bempedoic acid may offer a practical lower-risk alternative. The 2022 ACC Expert Consensus Decision Pathway on Statin Intolerance provides guidance for this population.

Statin Intolerance: Definition and Practical Assessment

"Statin intolerance" is often overdiagnosed. The SAMSON trial (N=60, crossover design) found that 90% of reported muscle symptom burden during statin use could not be distinguished from placebo. Nocebo effects account for a substantial share of real-world discontinuation. SAMSON was published in the New England Journal of Medicine in 2020.

Before labeling a patient statin-intolerant, current guidance recommends:

1. Confirm the muscle symptoms with a CK measurement.
2. Attempt a lower dose of the same statin.
3. Switch to a different statin, particularly hydrophilic agents like rosuvastatin or pravastatin.
4. Try alternate-day dosing with rosuvastatin (5 to 10 mg every other day), which has shown LDL-C reductions of 20 to 35% with fewer muscle complaints in observational series.
5. Document failure of at least two statins at the lowest available dose before declaring complete intolerance.

The 2022 ACC Expert Consensus Decision Pathway defines "statin intolerance" as the inability to tolerate two or more statins, at least one at the lowest approved starting dose, due to objectively confirmed adverse effects. Only after this threshold is met should bempedoic acid move up to a primary role. For patients meeting that definition, bempedoic acid 180 mg daily (or Nexlizet if further LDL lowering is needed) is the most evidence-backed oral alternative available today.

Lisinopril vs Losartan: A Brief Note on Companion Cardiometabolic Therapy

Many patients on lipid-lowering therapy also carry a diagnosis of hypertension or diabetic nephropathy and need a renin-angiotensin system (RAS) blocker. ACE inhibitors like lisinopril and ARBs like losartan are both guideline-recommended. Lisinopril reduces blood pressure through bradykinin potentiation in addition to angiotensin II blockade, which may contribute to its persistent dry cough in 10 to 15% of patients. Losartan blocks only the AT1 receptor; cough rates are near placebo. Both classes reduce cardiovascular mortality in heart failure with reduced ejection fraction and slow progression of diabetic nephropathy. A 2018 Cochrane review found no significant difference in cardiovascular outcomes between ACE inhibitors and ARBs for hypertension.

The choice between them is often symptom-driven: a patient who develops cough on lisinopril is a reasonable candidate for losartan. Combining them (as tested in the ONTARGET trial, N=25,620) does not reduce MACE and increases the risk of acute kidney injury; guidelines advise against dual RAS blockade. ONTARGET outcomes were published in the New England Journal of Medicine.

Metoprolol vs Carvedilol in Cardiometabolic Disease

Beta-blockers often appear on the medication lists of patients also receiving statins or bempedoic acid, particularly those with coronary artery disease, heart failure with reduced ejection fraction, or atrial fibrillation. Metoprolol succinate (a selective beta-1 blocker) and carvedilol (a nonselective beta-1/beta-2/alpha-1 blocker) are both Class I guideline recommendations for heart failure with reduced ejection fraction (HFrEF).

Carvedilol's alpha-1 blockade adds vasodilatory effects and may produce greater afterload reduction, but it also causes more hypotension and dizziness at initiation. The COMET trial (N=3,029) compared carvedilol to immediate-release metoprolol tartrate and found a mortality benefit favoring carvedilol (34% vs 40% all-cause mortality, P<0.0017). However, the comparator was not metoprolol succinate, the formulation with proven mortality benefit in MERIT-HF. COMET was published in The Lancet. Most cardiologists consider the two agents broadly equivalent for HFrEF when used at target doses.

In patients without HFrEF who need beta-blockade for rate control or post-MI protection, metoprolol succinate is usually preferred because its metabolic profile is slightly more favorable: carvedilol's beta-2 blockade can worsen insulin resistance and mask hypoglycemia symptoms in patients with diabetes.

Eliquis vs Xarelto: Anticoagulation Context for High-Risk Patients

Patients managing complex cardiometabolic disease sometimes carry concurrent atrial fibrillation or venous thromboembolism, bringing direct oral anticoagulants (DOACs) into the medication picture. Apixaban (Eliquis) and rivaroxaban (Xarelto) are both factor Xa inhibitors, but they differ in dosing frequency and bleeding profile.

Apixaban is dosed twice daily; rivaroxaban once daily. In the ARISTOTLE trial (N=18,201), apixaban reduced stroke or systemic embolism by 21% vs warfarin with a 31% reduction in major bleeding. ARISTOTLE was published in the New England Journal of Medicine. In ROCKET-AF (N=14,264), rivaroxaban was non-inferior to warfarin for stroke prevention with similar major bleeding rates but a higher rate of gastrointestinal bleeding. ROCKET-AF results are on the New England Journal of Medicine site.

For patients who are also on a statin or bempedoic acid, the main concern is additive bleeding risk from any antiplatelet agents in the regimen. Neither statins nor bempedoic acid significantly affect DOAC pharmacokinetics, so no dose adjustments are required for that combination specifically.

How to Choose: A Clinical Decision Framework

The following framework reflects current ACC/AHA guideline recommendations combined with the CLEAR Outcomes data and the 2022 ACC Expert Consensus on Statin Intolerance. It is intended as a starting point for shared clinical decision-making, not a replacement for individualized assessment.

Step 1. Establish baseline LDL-C, ApoB, and 10-year ASCVD risk. Use the Pooled Cohort Equations for primary prevention patients. Obtain ApoB if the patient has hypertriglyceridemia (triglycerides >150 mg/dL), metabolic syndrome, or diabetes, since LDL-C may underestimate atherogenic particle burden in those groups.

Step 2. Select statin intensity based on risk tier.

• Very high risk (established ASCVD): high-intensity statin targeting LDL-C <70 mg/dL (and ApoB <80 mg/dL per EAS 2023 consensus).
• High risk (10-year ASCVD 7.5 to 20%, or diabetes): moderate-to-high-intensity statin.
• Borderline risk (5 to 7.5%): discuss statin initiation; coronary artery calcium score can guide shared decision-making.

Step 3. Address inadequate response or statin intolerance.

• Inadequate LDL-C response on maximally tolerated statin: add ezetimibe 10 mg first (cheapest, well-tolerated), then reassess. If still not at goal, add a PCSK9 inhibitor (evolocumab or alirocumab) or bempedoic acid depending on cost-access and patient preference.
• Confirmed statin intolerance (two statins failed at lowest dose): start bempedoic acid 180 mg daily. If the LDL-C target remains unmet, switch to Nexlizet (bempedoic acid 180 mg / ezetimibe 10 mg). Check uric acid at baseline and 12 weeks; withhold in patients with active gout.

Step 4. Monitor ApoB alongside LDL-C in patients with diabetes, metabolic syndrome, or persistent hypertriglyceridemia. A treated ApoB above 80 mg/dL in a very-high-risk patient warrants intensification even if LDL-C appears controlled.

Step 5. Document the rationale for any non-statin primary therapy in the chart. Payers require documented statin intolerance for prior authorization of bempedoic acid in most formularies.

The 2022 ACC Expert Consensus Decision Pathway on Statin Intolerance states: "For patients with statin intolerance, bempedoic acid, ezetimibe, and PCSK9 inhibitors are the primary therapeutic options to achieve LDL-C goals, with therapy selection guided by tolerability, magnitude of LDL-C reduction needed, and cost." Full pathway available via the Journal of the American College of Cardiology.

The CLEAR Outcomes principal investigator Dr. Steven Nissen stated in the NEJM publication discussion: "These findings support the use of bempedoic acid to reduce the risk of cardiovascular events in patients who are unable to take statins." Source: NEJM, March 2023.

A high-intensity statin remains the most cost-effective first choice. Generic rosuvastatin 20 mg costs roughly $6, $10 per month at major pharmacy chains. Bempedoic acid list price is approximately $330/month, and the fixed-dose Nexlizet runs close to $400/month without insurance. Manufacturer copay cards can reduce out-of-pocket costs substantially for commercially insured patients; prior authorization requirements vary widely by payer.